These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15496647)

  • 41. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
    Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
    Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
    Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
    Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
    Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
    Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxcarbazepine: new preparation. An alternative to carbamazepine in partial epilepsy.
    Prescrire Int; 2001 Dec; 10(56):170-4. PubMed ID: 11824439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxcarbazepine in the treatment of early childhood epilepsy.
    Gaily E; Granström ML; Liukkonen E
    J Child Neurol; 1997 Nov; 12(8):496-8. PubMed ID: 9430314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
    Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
    Keränen T; Sorri A; Moilanen E; Ylitalo P
    Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
    Otoul C; De Smedt H; Stockis A
    Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
    Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
    Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
    Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
    Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
    Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxcarbazepine.
    Beydoun A; Kutluay E
    Expert Opin Pharmacother; 2002 Jan; 3(1):59-71. PubMed ID: 11772334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
    Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
    Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma level monitoring of oxcarbazepine in epileptic patients.
    González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
    Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine.
    Dickinson RG; Hooper WD; Pendlebury SC; Moses D; Eadie MJ
    Clin Exp Neurol; 1988; 25():127-33. PubMed ID: 3077098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
    Sattler A; Schaefer M; May TW
    Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic drug monitoring of oxcarbazepine].
    Bouquié R; Dailly E; Bentué-Ferrer D;
    Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.